MOLECULAR MECHANISMS OF POSSIBLE USE OF METABOLITES FOR PREVENTION, THERAPY AND REHABILITATION OF PATIENTS WITH COVID-19

DOI: https://doi.org/10.29296/24999490-2021-06-02

E.V. Mashkovtseva, Ya.R. Nartsissov Institute of Cytochemistry and Molecular Pharmacology, Russian Federation, Moscow, 115404 24/14, 6th Radial’naya str. Е-mail: [email protected]

The purpose of this review was to describe information about the etiology and pathogenesis of the main manifestations in patients with coronavirus infection COVID-19 and the molecular mechanisms of the possible use of metabolite drugs. Material and methods. The full-text search has been carried out in the Medline (Pubmed) and Scopus databases over the past 15 years. Results. Based on the results of the analysis the mechanisms of microcirculation disorders, possible ways of the virus penetration into the central nervous system and its effect on brain cells are described in detail. Neuronal damage and disruption of their normal functioning can lead to long-term consequences of infection. The use of metabolites to correct the cell state can soflty reduce inflammation through a range of molecular mechanisms. Conclusions. The proven cytoprotective and immunomodulatory effect of glycine determines its possible use in the therapy of COVID-19. The use of antioxidants such as glutathione is pathogenetically justified for the correction of endothelial dysfunction and neuronal hypoxia.
Keywords: 
COVID-19, central nervous system impairment, microcirculation, molecular mechanisms, metabolic therapy, glycine

Список литературы: 
  1. Sajt Vsemirnoj organizatsii zdravoohranenija www.who.int. [Website of the World Health Organization www.who.int (in Russian)]
  2. Gencer S., Lacy M., Atzler D., van der Vorst E. P. C., Doring Y., Weber C. Immuno-inflammatory, thrombo-haemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost. 2020; 120 (12): 1629–41. https://doi:10.1055/s-0040-1718735
  3. Yin J., Wang S., Liu Y., Chen J., Li D., Xu T. Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation. 2021; 28 (7): e12718. https://doi:10.1111/micc.12718
  4. Zakeri A., Jadhav A.P., Sullenger B.A., Nimjee S.M. Ischemic stroke in COVID-19-positive patients: An overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J. Neurointerv Surg. 2021; 13 (3): 202–6. https://doi:10.1136/neurintsurg-2020-016794
  5. The Task Force for the management of COVID-19 of the European Society of Cardiology. European society of cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1 – epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2021; 00: 1–26. https://doi:10.1093/eurheartj/ehab696
  6. Capettini L.S., Montecucco F., Mach F., Stergiopulos N., Santos R. A., da Silva R.F. Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des. 2012; 18 (7): 963–70. https://doi:10.2174/138161212799436593
  7. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203 (2): 631–7. https://doi:10.1002/path.1570
  8. Gasecka A., Filipiak K.J., Jaguszewski M.J. Impaired microcirculation function in COVID-19 and implications for potential therapies. Cardiol J. 2020; 27 (5): 485–8. https://doi:10.5603/CJ.2020.0154
  9. Martynov M.Ju., Bogolepova A.N., Jasamanova A.N. Endotelial'naja disfunktsija pri COVID-19 i kognitivnye narushenija. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2021; 121 (6): 93–9. https://doi:10.17116/jnevro202112106193. [Martynov M.Y., Bogolepova A.N., Yasamanova A.N. Endothelial dysfunction in COVID- 19 and cognitive impairment. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2021; 121 (6): 93–9 (in Russian)]
  10. Yan Z., Yang M., Lai C.L. Long COVID-19 syndrome: A comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021; 9 (8). https://doi:10.3390/biomedicines9080966
  11. Ostergaard L. SARS-CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021; 9 (3): e14726. https://doi:10.14814/phy2.14726
  12. Akin S., van Hooven D., Ince C., Jansen T. Veno-arterial thrombosis and microcirculation imaging in a patient with COVID-19. Respir Med Case Rep. 2021; 33: 101428. https://doi:10.1016/j.rmcr.2021.101428
  13. Scorcella C., Damiani E., Domizi R., Pierantozzi S., Tondi S., Carsetti A., Ciucani S., Monaldi V., Rogani M., Marini B., Adrario E., Romano R., Ince C., Boerma E.C., Donati, A. MicroDAIMON study: Microcirculatory DAIly MONitoring in critically ill patients: A prospective observational study. Ann Intensive Care. 2018; 8 (1): 64. https://doi:10.1186/s13613-018-0411-9
  14. Gusev E., Sarapultsev A., Hu D., Chereshnev V. Problems of pathogenesis and pathogenetic therapy of COVID-19 from the perspective of the general theory of pathological systems (general pathological processes). Int J. Mol Sci. 2021; 22 (14). https://doi:10.3390/ijms22147582
  15. Lysenkov S.P., Muzhenya D.V., Tuguz A.R., Urakova T.U., Shumilov D.S., Thakushinov I.A. Participation of nitrogen oxide and its metabolites in the genesis of hyperimmune inflammation in COVID-19. Chin J. Physiol. 2021; 64 (4): 167–76. https://doi:10.4103/cjp.cjp_38_21
  16. Mario L., Roberto M., Marta L., Teresa C.M., Laura M. Hypothesis of COVID-19 therapy with sildenafil. Int J. Prev Med. 2020; 11: 76. https://doi:10.4103/ijpvm.IJPVM_258_20
  17. Singh K.K., Chaubey G., Chen J.Y., Suravajhala, P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am. J. Physiol Cell Physiol. 2020; 319 (2): 258–67. https://doi:10.1152/ajpcell.00224.2020
  18. Colombo D., Falasca L., Marchioni L., Tammaro A., Adebanjo G. A.R., Ippolito G., Zumla A., Piacentini M., Nardacci R., Del Nonno F. Neuropathology and inflammatory cell characterization in 10 autoptic COVID-19 brains. Cells. 2021; 10 (9). https://doi:10.3390/cells10092262
  19. Alquisiras-Burgos I., Peralta-Arrieta I., Alonso-Palomares L.A., Zacapala-Gomez A.E., Salmeron-Barcenas E.G., Aguilera P. Neurological complications associated with the blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection. Mol. Neurobiol. 2021; 58 (2): 520–35. https://doi:10.1007/s12035-020-02134-7
  20. Desforges M., Le Coupanec A., Stodola J.K., Meessen-Pinard M., Talbot P.J. Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res. 2014; 194: 145–58. https://doi:10.1016/j.virusres.2014.09.011
  21. Koyuncu O.O., Hogue I.B., Enquist L.W. Virus infections in the nervous system. Cell Host Microbe. 2013; 13 (4): 379–93. https://doi:10.1016/j.chom.2013.03.010
  22. Nagu P., Parashar A., Behl T., Mehta V. CNS implications of COVID-19: A comprehensive review. Rev Neurosci. 2021; 32 (2): 219–34. https://doi:10.1515/revneuro-2020-0070
  23. McGavern D.B., Kang S.S. Illuminating viral infections in the nervous system. Nat Rev Immunol. 2011; 11 (5): 318–29. https://doi:10.1038/nri2971
  24. Ogier M., Andeol, G., Sagui E., Dal Bo G. How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav Immun Health. 2020; 5: 100081. https://doi:10.1016/j.bbih.2020.100081
  25. Yachou Y., El Idrissi A., Belapasov V., Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: Understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020; 41 (10): 2657–69. https://doi:10.1007/s10072-020-04575-3
  26. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig, A.S., Shalev D., Sehrawat T.S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G.F., Bernstein E.J., Mohan S., Beckley A.A., Seres D.S., Choueiri T.K., Uriel N., Ausiello J.C., Accili D., Freedberg D.E., Baldwin M., Schwartz A., Brodie D., Garcia C.K., Elkind M.S.V., Connors J.M., Bilezikian J.P., Landry D.W., Wan E.Y. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15. https://doi:10.1038/s41591-021-01283-z
  27. Buoite Stella A., Furlanis G., Frezza N.A., Valentinotti R., Ajcevic M., Manganotti P. Autonomic dysfunction in post-COVID patients with and without neurological symptoms: A prospective multidomain observational study. J. Neurol. 2021. https://doi:10.1007/s00415-021-10735-y
  28. Stefano G.B., Ptacek R., Ptackova H., Martin A., Kream R.M. Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce ‘brain fog’ and results in behavioral changes that favor viral survival. Med Sci Monit. 2021; 27: e930886. https://doi:10.12659/MSM.930886
  29. Liu Y., Wang X., Hu C.A. Therapeutic potential of amino acids in inflammatory bowel disease. Nutrients. 2017; 9 (9). https://doi:10.3390/nu9090920
  30. Weinberg J.M., Bienholz A., Venkatachalam M.A. The role of glycine in regulated cell death. Cellular and molecular life sciences: CMLS. 2016; 73 (11–12): 2285–308. https://doi:10.1007/s00018-016-2201-6
  31. Nartsissov Ja.R., Kopylova V.S., Mashkovtseva E.V., Boronovskij S.E. Izmenenie nestatsionarnyh gradientov gidroperekisi v ochage reoksigenatsii pod dejstviem glitsina pri eksajtotoksichnosti. Molekuljarnaja meditsina. 2018; 16 (3): 37–41. https://doi: 10.29296/24999490-2018-03-07 [Nartsissov Ya.R, Kopylova V.S., Mashkovtseva E.V., Boronovskiy S.E. Alteration of hydroperoxide non-steady state gradients in the reoxygenation nidus exposed to glycine under excitotoxicity. Molekulyarnaya meditsina. 2018; 16 (3): 37–41 (in Russian)]
  32. Yin M., Rusyn I., Schoonhoven R., Graves L.M., Rusyn E.V., Li X., Cox A.D., Harding T.W., Bunzendahl H., Swenberg J.A., Thurman R.G. Inhibition of chronic rejection of aortic allografts by dietary glycine. Transplantation. 2000; 69 (5): 773–80. https://doi:10.1097/00007890-200003150-00017
  33. Selin A.A., Lobysheva N.V., Vorontsova O.N., Ton'shin A.A., Jaguzhinskij L.S., Nartsissov Ja.R. Mehanizm dejstvija glitsina kak protektora narushenija energetiki tkanej mozga v uslovijah gipoksii. Bjulleten' eksperimental'noj biologii i meditsiny. 2012; 153 (1): 52–5. [Selin A.A., Lobysheva N.V., Vorontsova O.N., Nartsissov Ya.R., Tonshin A.A., Yaguzhinsky L.S. Mechanism underlying the protective effect of glycine in energetic disturbances in brain tissues under hypoxic conditions. Bulletin of Experimental Biology and Medicine. 2012; 153 (1): 52–5 (in Russian)]
  34. Lobysheva N.V., Selin A.A., Vangeli I.M., Byvshev I.M., Yaguzhinsky L.S., Nartsissov Y.R. Glutamate induces H2O2 synthesis in nonsynaptic brain mitochondria. Free Radic Biol Med. 2013; 65: 428–35. https://doi:10.1016/j.freeradbiomed.2013.07.030
  35. Petrat F., Boengler K., Schulz R., de Groot H. Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: Current knowledge. Br. J. Pharmacol. 2012; 165 (7): 2059–72. https://doi:10.1111/j.1476-5381.2011.01711.x
  36. Hasegawa S., Ichiyama T., Sonaka I., Ohsaki A., Okada S., Wakiguchi H., Kudo K., Kittaka S., Hara M., Furukawa S. Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells. Clin Exp Immunol. 2012; 167 (2): 269–74. https://doi:10.1111/j.1365-2249.2011.04519.x
  37. Mauerhofer C., Grumet L., Schemmer P., Leber B., Stiegler P. Combating ischemia-reperfusion injury with micronutrients and natural compounds during solid organ transplantation: Data of clinical trials and lessons of preclinical findings. Int J. Mol. Sci. 2021; 22 (19). https://doi:10.3390/ijms221910675
  38. Xanthos D.N., Sandkuhler J. Neurogenic neuroinflammation: Inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci. 2014; 15 (1): 43–53. https://doi:10.1038/nrn3617
  39. Silvagno F., Vernone A., Pescarmona G.P. The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants (Basel, Switzerland). 2020; 9 (7): 624. https://doi:10.3390/antiox9070624
  40. DeDiego M.L., Nieto-Torres J.L., Regla-Nava J.A., Jimenez-Guardeno J.M., Fernandez-Delgado R., Fett C., Castano-Rodriguez C., Perlman S., Enjuanes L. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 2014; 88 (2): 913–24. https://doi:10.1128/JVI.02576-13
  41. Wheeler M.D., Thurman R.G. Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine. Am. J. Physiol. 1999; 277 (5): 952–9. https://doi:10.1152/ajplung.1999.277.5.L952
  42. Carella A.M., Benvenuto A., Lagattolla V., Marinelli T., De Luca P., Ciavarrella G., Modola G., Di Pumpo M., Ponziano E., Benvenuto M. Vitamin supplements in the Era of SARS-Cov2 pandemic. GSC Biological and Pharmaceutical Sciences. 2020; 11 (02): 7–19. https://doi: 10.30574/gscbps.2020.11.2.0114
  43. Wintergerst E.S., Maggini S., Hornig D.H. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab. 2007; 51 (4): 301–23. https://doi:10.1159/000107673
  44. Shakoor H., Feehan J., Mikkelsen K., Al Dhaheri A.S., Ali H.I., Platat C., Ismail L.C., Stojanovska L., Apostolopoulos V. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021; 144: 108–11. https://doi:10.1016/j.maturitas.2020.08.007
  45. Prihod'ko V.A., Selizarova N.O., Okovityj S.V. Molekuljarnye mehanizmy razvitija gipoksii i adaptatsii k nej. Chast' I. Arhiv patologii. 2021; 83 (2): 52–61. [Prikhodko V.A, Selizarova N.O, Okovityi S.V. Molecular mechanisms for hypoxia development and adaptation to it. Part I. Arkhiv Patologii. 2021; 83 (2): 52–61 (in Russian)]
  46. Strahov I.V., Ariskina O.B., Sokornov I.A. Vozmozhnosti korrektsii oksidativnogo stressa u postradavshih s shokogennoj travmoj. Efferentnaja terapija. 2009; 15 (1–2): 195. [Strakhov I.V., Ariskina I.A., Sokornov I.A. Oxidative stress correction possibilities in patients with shock injury. Efferentnaya terapiya. 2009; 15 (1–2): 195 (in Russian)]
  47. Luk'janova L.D. Signal'nye mehanizmy gipoksii. M.: RAN, 2019. [Lukianova L.D. Signal mechanisms of transduction. M.: RAN, 2019